Actinogen Says No Unannounced Information Behind Trading, Points to Mid-November Trial Results
ACW: $0.048 +17.07% · MC: $182M
Actinogen Medical told the ASX it knows of no unannounced information that could explain recent trading in its shares. It pointed to its October update that the XanaMIA Alzheimer’s trial had reached database lock, with topline results expected in mid-November 2026.

Comments